Overview
IconOVir Bio is a preclinical-stage biotechnology company that endeavors to pioneer the next generation of oncolytic virus therapies for cancer treatment. The company leverages advanced scientific research to develop targeted cancer therapies that could revolutionize cancer treatment. IconOVir is located at 689 Fifth Ave, 12th Floor, New York, NY 10022, operating prominently from San Diego, California.
Mission and Core Values
The mission of IconOVir Bio focuses on combating cancer through genetically advanced therapies that match the sophistication of the disease itself. This mission is exemplified by the development of rationally-designed oncolytic virus therapies with significant therapeutic benefits, as emphasized by Clodagh O’Shea, Ph.D., the company's Scientific Founder.
Management Team and Leadership
- Mark McCamish, M.D., Ph.D., serves as President & CEO, driving the company’s exploration of transformative oncolytic viral platforms.
- Heba Nowyhed, Ph.D., Chief Scientific Officer, contributes over 15 years of expertise in translational immunobiology.
- John Huynh, Ph.D., Chief Technology Officer, oversees manufacturing and technical operations, ensuring quality CMC processes.
- Julie Maltzman, M.D., Chief Medical Officer, brings extensive clinical oncology experience, focusing on drug development phases.
- Board and Advisors: Chaired by David Chang, M.D., Ph.D. The Scientific Advisory Board led by Clodagh O’Shea includes members like William Kaelin, M.D. from Dana-Farber Cancer Institute.
Additional Key Personnel:
- Benjamin Stone: Head of Business Operations
- Sean Algeo: Controller & Treasurer
- Nicole van de Leuv: Head of Legal
- Robert Quesenberry: Clinical Development Operations Leader
- Nathaniel Rice: Scientist, Translational Research
Financial Overview
- Total Financing: Raised $77 million in Series A with further funding totaling $97.2 million over two rounds, including a $20.23 million debt funding in June 2023.
- Estimated Annual Revenue: $1.9 million
- Total Employees: 24, with a revenue per employee estimated at approximately $77,500.
- Employee Growth: Experienced a 47% decline over the past year.
Products and Development Pipeline
IconOVir Bio’s key candidate, ICVB-1042, is a leading oncolytic virus therapy showing promising potential against solid tumors. Significant presentations, backed by scientific evidence, highlight the exceptional potential of ICVB-1042 in selectively targeting tumor cells.
Recent Developments
In July 2023, the company dosed the first patient in a Phase 1 clinical trial for ICVB-1042, demonstrating a shift from preclinical phases to therapeutic applications. IconOVir Bio also actively participates in healthcare conferences to present their innovative developments.
Competitive Landscape
IconOVir Bio resides within a competitive field, countered by firms such as:
1. Plexxikon
2. IMPACT Therapeutics
3. Chipscreen Biosciences
4. TenNor Therapeutics
5. Inovio Pharmaceuticals
6. Fekra Therapeutics
7. EV Therapeutics
8. Jazz Pharmaceuticals
9. C4 Therapeutics
10. Erasca
Competitor Insights
- DiaCarta: Specializes in precision diagnostics with revenue of $4.4M and 57 employees.
- Mission Bio: Focuses on single-cell technologies, reported revenue of $21.2M and 137 employees.
- Quadrants Scientific: Provides FDA-regulated technical support, with a revenue of $0.9M and 6 employees.
Strategic Vision
IconOVir Bio, despite being at its preclinical stage, stands distinctively with impactful scientific approaches underpinned by substantial funding. It strives for significant breakthroughs in oncolytic virus therapies, targeting unexplored opportunities in cancer treatment and prospective partnerships in the oncology field.
Contact Information
For partnerships and media inquiries, contact:
- Partnering: info@iconovir.com
- Media: media@iconovir.com
